Treatment of diencephalic syndrome with chemotherapy: Growth, tumor response, and long term control

Andrea L. Gropman, Roger J. Packer, H. Stacy Nicholson, L. Gilbert Vezina, Regina Jakacki, Russell Geyer, James M. Olson, Peter Phillips, Michael Needle, Emmett H. Broxson, Gregory Reaman, Jonathan Finlay

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

BACKGROUND. The diencephalic syndrome (DS), which is manifested by progressive emaciation and failure to thrive in an apparently alert, cheerful infant, usually is due to a low grade hypothalamic glioma. Treatment with aggressive surgery and/or radiotherapy is variably successful in controlling disease and may result in severe neurologic sequelae. Chemotherapy recently has been shown to be effective in patients with low grade gliomas of childhood, but it is used infrequently in those with DS. METHODS. The authors evaluated the efficacy of a regimen of carboplatin and vincristine on improving weight, causing tumor shrinkage, and delaying the need for alternative therapies in seven children (ages 9-20 months; median age, 11 months) with DS. Five patients weighed less than the 5th percentile for their age at the start of the study, one weighed within the 10th percentile, and one weighed within the 25th percentile. RESULTS. At follow-up (range, 6-54 months; median, 28 months), the patients' weights had increased by 66-95% (median, 80%). On magnetic resonance imaging, four patients had a >50% reduction in tumor mass, one had a 25-50% reduction, and two had stable disease. In those patients with radiographic response to treatment, weight gain was accomplished with oral feedings in four of five patients, whereas those with stable disease required nasogastric, nasojejunal, or gastrostomy tube supplementation to maintain weight. Disease progression occurred at a median of 24 months after initiation of chemotherapy, and two patients remained free of progressive disease at last follow-up. Five patients were alive a median of 59 months from diagnosis. The need for radiation or other therapies was delayed in six of seven children. Therapy was tolerated without significant toxicities. CONCLUSION. The authors conclude that treatment of DS with a carboplatin and vincristine regimen results in demonstrable weight gain, may result in tumor shrinkage, and in some cases, significantly delays the need for alternative therapies.

Original languageEnglish (US)
Pages (from-to)166-172
Number of pages7
JournalCancer
Volume83
Issue number1
DOIs
StatePublished - Jul 1 1998
Externally publishedYes

Fingerprint

Drug Therapy
Growth
Neoplasms
Carboplatin
Vincristine
Therapeutics
Complementary Therapies
Glioma
Weight Gain
Emaciation
Weights and Measures
Failure to Thrive
Gastrostomy
Tumor Burden
Nervous System
Disease Progression
Radiotherapy
Magnetic Resonance Imaging
Radiation

Keywords

  • Brain tumor
  • Chemotherapy
  • Diencephalic syndrome
  • Glioma
  • Hypothalamic glioma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gropman, A. L., Packer, R. J., Nicholson, H. S., Vezina, L. G., Jakacki, R., Geyer, R., ... Finlay, J. (1998). Treatment of diencephalic syndrome with chemotherapy: Growth, tumor response, and long term control. Cancer, 83(1), 166-172. https://doi.org/10.1002/(SICI)1097-0142(19980701)83:1<166::AID-CNCR22>3.0.CO;2-U

Treatment of diencephalic syndrome with chemotherapy : Growth, tumor response, and long term control. / Gropman, Andrea L.; Packer, Roger J.; Nicholson, H. Stacy; Vezina, L. Gilbert; Jakacki, Regina; Geyer, Russell; Olson, James M.; Phillips, Peter; Needle, Michael; Broxson, Emmett H.; Reaman, Gregory; Finlay, Jonathan.

In: Cancer, Vol. 83, No. 1, 01.07.1998, p. 166-172.

Research output: Contribution to journalArticle

Gropman, AL, Packer, RJ, Nicholson, HS, Vezina, LG, Jakacki, R, Geyer, R, Olson, JM, Phillips, P, Needle, M, Broxson, EH, Reaman, G & Finlay, J 1998, 'Treatment of diencephalic syndrome with chemotherapy: Growth, tumor response, and long term control', Cancer, vol. 83, no. 1, pp. 166-172. https://doi.org/10.1002/(SICI)1097-0142(19980701)83:1<166::AID-CNCR22>3.0.CO;2-U
Gropman, Andrea L. ; Packer, Roger J. ; Nicholson, H. Stacy ; Vezina, L. Gilbert ; Jakacki, Regina ; Geyer, Russell ; Olson, James M. ; Phillips, Peter ; Needle, Michael ; Broxson, Emmett H. ; Reaman, Gregory ; Finlay, Jonathan. / Treatment of diencephalic syndrome with chemotherapy : Growth, tumor response, and long term control. In: Cancer. 1998 ; Vol. 83, No. 1. pp. 166-172.
@article{8a7916434e544d01a15cd6966305f25e,
title = "Treatment of diencephalic syndrome with chemotherapy: Growth, tumor response, and long term control",
abstract = "BACKGROUND. The diencephalic syndrome (DS), which is manifested by progressive emaciation and failure to thrive in an apparently alert, cheerful infant, usually is due to a low grade hypothalamic glioma. Treatment with aggressive surgery and/or radiotherapy is variably successful in controlling disease and may result in severe neurologic sequelae. Chemotherapy recently has been shown to be effective in patients with low grade gliomas of childhood, but it is used infrequently in those with DS. METHODS. The authors evaluated the efficacy of a regimen of carboplatin and vincristine on improving weight, causing tumor shrinkage, and delaying the need for alternative therapies in seven children (ages 9-20 months; median age, 11 months) with DS. Five patients weighed less than the 5th percentile for their age at the start of the study, one weighed within the 10th percentile, and one weighed within the 25th percentile. RESULTS. At follow-up (range, 6-54 months; median, 28 months), the patients' weights had increased by 66-95{\%} (median, 80{\%}). On magnetic resonance imaging, four patients had a >50{\%} reduction in tumor mass, one had a 25-50{\%} reduction, and two had stable disease. In those patients with radiographic response to treatment, weight gain was accomplished with oral feedings in four of five patients, whereas those with stable disease required nasogastric, nasojejunal, or gastrostomy tube supplementation to maintain weight. Disease progression occurred at a median of 24 months after initiation of chemotherapy, and two patients remained free of progressive disease at last follow-up. Five patients were alive a median of 59 months from diagnosis. The need for radiation or other therapies was delayed in six of seven children. Therapy was tolerated without significant toxicities. CONCLUSION. The authors conclude that treatment of DS with a carboplatin and vincristine regimen results in demonstrable weight gain, may result in tumor shrinkage, and in some cases, significantly delays the need for alternative therapies.",
keywords = "Brain tumor, Chemotherapy, Diencephalic syndrome, Glioma, Hypothalamic glioma",
author = "Gropman, {Andrea L.} and Packer, {Roger J.} and Nicholson, {H. Stacy} and Vezina, {L. Gilbert} and Regina Jakacki and Russell Geyer and Olson, {James M.} and Peter Phillips and Michael Needle and Broxson, {Emmett H.} and Gregory Reaman and Jonathan Finlay",
year = "1998",
month = "7",
day = "1",
doi = "10.1002/(SICI)1097-0142(19980701)83:1<166::AID-CNCR22>3.0.CO;2-U",
language = "English (US)",
volume = "83",
pages = "166--172",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Treatment of diencephalic syndrome with chemotherapy

T2 - Growth, tumor response, and long term control

AU - Gropman, Andrea L.

AU - Packer, Roger J.

AU - Nicholson, H. Stacy

AU - Vezina, L. Gilbert

AU - Jakacki, Regina

AU - Geyer, Russell

AU - Olson, James M.

AU - Phillips, Peter

AU - Needle, Michael

AU - Broxson, Emmett H.

AU - Reaman, Gregory

AU - Finlay, Jonathan

PY - 1998/7/1

Y1 - 1998/7/1

N2 - BACKGROUND. The diencephalic syndrome (DS), which is manifested by progressive emaciation and failure to thrive in an apparently alert, cheerful infant, usually is due to a low grade hypothalamic glioma. Treatment with aggressive surgery and/or radiotherapy is variably successful in controlling disease and may result in severe neurologic sequelae. Chemotherapy recently has been shown to be effective in patients with low grade gliomas of childhood, but it is used infrequently in those with DS. METHODS. The authors evaluated the efficacy of a regimen of carboplatin and vincristine on improving weight, causing tumor shrinkage, and delaying the need for alternative therapies in seven children (ages 9-20 months; median age, 11 months) with DS. Five patients weighed less than the 5th percentile for their age at the start of the study, one weighed within the 10th percentile, and one weighed within the 25th percentile. RESULTS. At follow-up (range, 6-54 months; median, 28 months), the patients' weights had increased by 66-95% (median, 80%). On magnetic resonance imaging, four patients had a >50% reduction in tumor mass, one had a 25-50% reduction, and two had stable disease. In those patients with radiographic response to treatment, weight gain was accomplished with oral feedings in four of five patients, whereas those with stable disease required nasogastric, nasojejunal, or gastrostomy tube supplementation to maintain weight. Disease progression occurred at a median of 24 months after initiation of chemotherapy, and two patients remained free of progressive disease at last follow-up. Five patients were alive a median of 59 months from diagnosis. The need for radiation or other therapies was delayed in six of seven children. Therapy was tolerated without significant toxicities. CONCLUSION. The authors conclude that treatment of DS with a carboplatin and vincristine regimen results in demonstrable weight gain, may result in tumor shrinkage, and in some cases, significantly delays the need for alternative therapies.

AB - BACKGROUND. The diencephalic syndrome (DS), which is manifested by progressive emaciation and failure to thrive in an apparently alert, cheerful infant, usually is due to a low grade hypothalamic glioma. Treatment with aggressive surgery and/or radiotherapy is variably successful in controlling disease and may result in severe neurologic sequelae. Chemotherapy recently has been shown to be effective in patients with low grade gliomas of childhood, but it is used infrequently in those with DS. METHODS. The authors evaluated the efficacy of a regimen of carboplatin and vincristine on improving weight, causing tumor shrinkage, and delaying the need for alternative therapies in seven children (ages 9-20 months; median age, 11 months) with DS. Five patients weighed less than the 5th percentile for their age at the start of the study, one weighed within the 10th percentile, and one weighed within the 25th percentile. RESULTS. At follow-up (range, 6-54 months; median, 28 months), the patients' weights had increased by 66-95% (median, 80%). On magnetic resonance imaging, four patients had a >50% reduction in tumor mass, one had a 25-50% reduction, and two had stable disease. In those patients with radiographic response to treatment, weight gain was accomplished with oral feedings in four of five patients, whereas those with stable disease required nasogastric, nasojejunal, or gastrostomy tube supplementation to maintain weight. Disease progression occurred at a median of 24 months after initiation of chemotherapy, and two patients remained free of progressive disease at last follow-up. Five patients were alive a median of 59 months from diagnosis. The need for radiation or other therapies was delayed in six of seven children. Therapy was tolerated without significant toxicities. CONCLUSION. The authors conclude that treatment of DS with a carboplatin and vincristine regimen results in demonstrable weight gain, may result in tumor shrinkage, and in some cases, significantly delays the need for alternative therapies.

KW - Brain tumor

KW - Chemotherapy

KW - Diencephalic syndrome

KW - Glioma

KW - Hypothalamic glioma

UR - http://www.scopus.com/inward/record.url?scp=0032127349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032127349&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19980701)83:1<166::AID-CNCR22>3.0.CO;2-U

DO - 10.1002/(SICI)1097-0142(19980701)83:1<166::AID-CNCR22>3.0.CO;2-U

M3 - Article

C2 - 9655307

AN - SCOPUS:0032127349

VL - 83

SP - 166

EP - 172

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -